# ComGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/comgen

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.comgenpharma.com
- Total disclosed funding: $16M
- Latest round: Series A (Nov 18, 2021)
- Investors on record: 4

## About

Based in Shanghai, China, and established in 2017, ComGen a R&D of drug company that drugs used  for treatment for autoimmune diseases and tumors. The company established by professor Mr. Guowei Hu who won the honors of Shanghai Oriental Scholar, and Outstanding Talents in the New Century by the Ministry of Education, with Suzhou Alphamab Co.,Ltd.

The company developed complement inhibitors for autoimmune diseases with excessive complement activation, and oncology R&D complement agonist for low immune activity, based on R&D and transformation platform of China's universities and Suzhou Alphamab Co.,Ltd., and self-complement technology platform. In 2021, it's new drug of new target complement inhibitors has obtained clinical license. Moreover, it has more than 10 drugs been developing, which used in treatment for tumors, autoimmune diseases, rare diseases.

The company plans to do first phase clinical trials of new drug of new target complement inhibitors, and advance the progress of other drugs. Moreover, it will continue to develop new drugs, based on the R&D drug platform of complement system.

## Funding rounds

- Series A, Nov 18, 2021, $16M — Hong Shan, Alwin Capital, Guangdong Fuchuang Investment Management, Chengdu Renyou Investment

## Investors

- Hong Shan — Series A
- Alwin Capital — Series A
- Guangdong Fuchuang Investment Management — Series A
- Chengdu Renyou Investment — Series A